19.06
-0.58 (-2.95%)
| Previous Close | 19.64 |
| Open | 19.40 |
| Volume | 758,604 |
| Avg. Volume (3M) | 1,132,772 |
| Market Cap | 1,398,563,584 |
| Price / Sales | 5.57 |
| Price / Book | 3.90 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -83.39% |
| Operating Margin (TTM) | -85.45% |
| Diluted EPS (TTM) | -2.63 |
| Quarterly Revenue Growth (YOY) | 62.70% |
| Total Debt/Equity (MRQ) | 31.15% |
| Current Ratio (MRQ) | 3.45 |
| Operating Cash Flow (TTM) | 25.97 M |
| Levered Free Cash Flow (TTM) | -17.73 M |
| Return on Assets (TTM) | -16.27% |
| Return on Equity (TTM) | -43.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bullish | Mixed |
| Health Information Services (Global) | Bullish | Mixed | |
| Stock | Schrodinger, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -2.5 |
| Average | -2.13 |
|
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.63% |
| % Held by Institutions | 101.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation Trust | 31 Mar 2025 | 6,981,664 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Keybanc, 57.40%) | Buy |
| Median | 22.50 (18.05%) | |
| Low | 19.00 (Morgan Stanley, -0.32%) | Hold |
| Average | 23.50 (23.30%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 20.00 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 18 Aug 2025 | 19.00 (-0.31%) | Hold | 20.05 |
| Citigroup | 15 Aug 2025 | 20.00 (4.93%) | Hold | 19.38 |
| Barclays | 14 Aug 2025 | 25.00 (31.16%) | Buy | 19.45 |
| Keybanc | 14 Jul 2025 | 30.00 (57.40%) | Buy | 21.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Schrödinger to Present at Morgan Stanley Global Healthcare Conference |
| 15 Aug 2025 | Announcement | Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 14 Aug 2025 | Announcement | Schrödinger Announces Discontinuation of SGR-2921 Program |
| 25 Jul 2025 | Announcement | Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 |
| 18 Jul 2025 | Announcement | Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 17 Jul 2025 | Announcement | Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target |
| 27 Jun 2025 | Announcement | Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia |
| 17 Jun 2025 | Announcement | Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |